Gyre Therapeutics profit margin GYRE

Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.

Net margin, 12 months: −15.5%
Operating margin, 12 months: −14.0%
Net margin on a year earlier: −17.1 pts
Peer median: 11.6%

Over the twelve months to Jun 30, 2026, Gyre Therapeutics kept −15.5% of its revenue as net profit, with an operating margin of −14.0% and a gross margin of 94.3%.

The median for 10 large drugmakers of a similar size is 11.6%.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal year	Net margin	Operating margin	Gross margin
FY2025	2.1%	5.9%	95.5%
FY2024	11.4%	15.3%	96.3%
FY2023	−81.9%	−59.3%	95.9%
FY2022	n/a	n/a	−0.5%
FY2021	n/a	n/a	−0.6%
FY2020	n/a	n/a	56.3%
FY2019	n/a	n/a	n/a
FY2018	n/a	n/a	n/a
FY2017	n/a	n/a	n/a
FY2016	n/a	n/a	n/a
FY2015	n/a	n/a	n/a
FY2014	n/a	n/a	n/a
FY2013	n/a	n/a	n/a
FY2012	−12.1%	−14.1%	n/a
FY2011	−8.7%	−10.0%	n/a

Quarter by quarter

Quarter	Ended	Net margin, 12 months	Change on a year	Operating margin
Q2 FY26	Jun 30, 2026	−15.5%	−17.1 pts	−14.0%
Q1 FY26	Mar 31, 2026	−7.4%	−14.6 pts	−3.8%
Q4 FY25	Dec 31, 2025	2.1%	−9.3 pts	5.9%
Q3 FY25	Sep 30, 2025	3.8%	+88.3 pts	6.9%
Q2 FY25	Jun 30, 2025	1.6%	+78.6 pts	4.7%
Q1 FY25	Mar 31, 2025	7.2%	+83.0 pts	10.3%
Q4 FY24	Dec 31, 2024	11.4%	+93.3 pts	15.3%
Q3 FY24	Sep 30, 2024	−84.6%	−47.0 pts	−72.5%
Q2 FY24	Jun 30, 2024	−77.0%	−1.0 pts	−60.6%
Q1 FY24	Mar 31, 2024	−75.8%	−110.0 pts	−56.9%
Q4 FY23	Dec 31, 2023	−81.9%	n/a	−59.3%
Q3 FY23	Sep 30, 2023	−37.5%	n/a	−18.4%

Against its peers

Companies in Drug Manufacturers - General nearest Gyre Therapeutics' size, closest first, today.

Company	Profit margin
GYREGyre Therapeutics	−15.5%
CRMDCorMedix	40.5%
ZVRAZevra Therapeutics	42.8%
IRWDIronwood Pharmaceuticals	33.4%
COLLCollegium Pharmaceutical	5.9%
PBYIPuma Biotechnology	11.6%
ABUSArbutus Biopharma	84.2%
ARVNArvinas	2.9%
AMPHAmphastar Pharmaceuticals	10.8%
OMEROmeros	n/m
PCRXPacira BioSciences	2.0%
Peer median	11.6%

Where Gyre Therapeutics ranks

#59of 84Large drugmakers with the highest profit margins

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Gyre Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.